Why Treace Medical Concepts, Inc.’s (TMCI) Stock Is Up 5.54%
As of Friday, August 14, Treace Medical Concepts, Inc.’s TMCI share price has surged by 5.54%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Treace Medical Concepts, Inc. (TMCI)
Treace Medical Concepts, Inc. TMCI
$4.79
0.28
6.21%
August 14, 2026 4:00:00 PM
EST
Volume: 245,390
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Commentary & Analysis
Why Treace Medical Concepts, Inc.’s (TMCI) Stock Is Up 5.71%
As of Friday, August 07, Treace Medical Concepts, Inc.’s TMCI share price has surged by 5.71%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Treace Medical Concepts, Inc.’s (TMCI) Stock Is Down 6.69%
As of Thursday, August 06, Treace Medical Concepts, Inc.’s TMCI share price has dipped by 6.69%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Treace Medical Concepts, Inc.’s (TMCI) Stock Is Up 6.03%
As of Monday, August 03, Treace Medical Concepts, Inc.’s TMCI share price has surged by 6.03%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Treace Medical Concepts, Inc.’s (TMCI) Stock Is Up 5.94%
As of Thursday, July 30, Treace Medical Concepts, Inc.’s TMCI share price has surged by 5.94%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | TMCI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $311.5 | $402.2 | 31% |
|
| Shares Out (Mil) | 65.0 | 41.4 | 54% |
|
| Institutional Ownership | 59.7% | 81.1% | 39% |
|
| Float (Mil) | 47.9 | 34.9 | 46% |
|
| Beta | 1.40 | 0.86 | 80% |
|
| Avg Daily Volume (000s) | 550 | 365 | 59% |
|
| Price Change (52-week) |
(30.6%) | 66.3% | 23% |
|
| Growth | TMCI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 29.9% | 11.8% | 90% |
|
| Net Income (5yr) | (74.0%) | (5.8%) | 3% |
|
| EPS (5yr) | (51.7%) | 10.6% | 3 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.6%) | (16.2%) | 48% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | na | 1 | |
| Current EPS | ($0.250) | ($0.851) | ($0.850) | |
| Month Ago EPS | ($0.240) | ($0.910) | ($0.900) | |
| # Rev Up | 1 | 3 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.240) | ($0.910) | ($0.900) | |
| Year/Year Chg | 2.5% | (8.8%) | (31.4%) | |
| Financials | TMCI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $205 | $140 | 32% |
|
| Net Income (TTM) (Mil) | ($60) | ($8) | 15% |
|
| EPS (TTM) | ($0.926) | ($0.400) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($2) | 17% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $1 | 52% |
|
| Long-Term Debt (Q1) (Mil) | $69 | $21 | 42% |
|
| Enterprise Value (Q1) (Mil) | $321 | $319 | 31% |
|
| Valuation | TMCI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.61 | 3.09 | 75% |
|
| P/E | na | 27.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | TMCI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 79.5% | 58.9% | 88% |
|
| Net Margin | (29.0%) | (6.9%) | 15% |
|
| ROA | (30.7%) | (13.3%) | 17% |
|
| ROE | (72.0%) | (11.4%) | 12% |
|
| Liabilities to Assets | 62.6% | 45.9% | 57% |
|
| F-Score | 2 | 4 | 7% |
|
Treace Medical Concepts, Inc. did not pass any screens on 8/14/2026.
